BiPar Sciences - Top 20 VC deals of 2008

BiPar Sciences, FierceBiotech's top venture capital deals of 2008Company: BiPar Sciences
Based: Brisbane, CA
Amount: $37.5 million

Investors: Domain Associates, Quantum Technology Partners, Undisclosed Venture Firm, Vulcan Capital, Lighthouse Capital Partners, Canaan Partners,PolyTechnos Venture-Partners, Asset Management Company Venture Capital

Scoop: BiPar Sciences' lead product, BSI-201, is designed to enhance the anti-tumor effects of chemotherapy. BSI-201 is in Phase II clinical studies of patients with triple negative breast cancer, ovarian cancer and other malignancies. The company has two other drugs in pre-clinical development: BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and BSI-302, a novel anti-tubulin therapy. BiPar already raised an additional $20 million in January 2009 to continue its work.

BiPar Sciences - Top 20 VC deals of 2008
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.